Front Row Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $349K | Hold |
287
| – | – | 0.1% | 89 |
|
|
2026
Q1 | $264K | Buy |
287
+5
| +2% | +$5.07K | 0.09% | 96 |
|
|
2025
Q4 | $303K | Hold |
282
| – | – | 0.1% | 88 |
|
|
2025
Q3 | $215K | Sell |
282
-7
| -2% | -$5.21K | 0.07% | 109 |
|
|
2025
Q2 | $225K | Sell |
289
-14
| -5% | -$10.9K | 0.08% | 102 |
|
|
2025
Q1 | $251K | Hold |
303
| – | – | 0.1% | 106 |
|
|
2024
Q4 | $234K | Hold |
303
| – | – | 0.08% | 108 |
|
|
2024
Q3 | $269K | Sell |
303
-963
| -76% | -$866K | 0.1% | 98 |
|
|
2024
Q2 | $1.15M | Sell |
1,266
-250
| -16% | -$200K | 0.4% | 54 |
|
|
2024
Q1 | $1.18M | Buy |
1,516
+963
| +174% | +$685K | 0.44% | 54 |
|
|
2023
Q4 | $323K | Sell |
553
-962
| -63% | -$562K | 0.15% | 78 |
|
|
2023
Q3 | $814K | Buy |
1,515
+107
| +8% | +$55.1K | 0.38% | 60 |
|
|
2023
Q2 | $660K | Hold |
1,408
| – | – | 0.29% | 67 |
|
|
2023
Q1 | $484K | Buy |
1,408
+53
| +4% | +$17.9K | 0.23% | 77 |
|
|
2022
Q4 | $496K | Sell |
1,355
-35
| -3% | -$12.4K | 0.26% | 77 |
|
|
2022
Q3 | $450K | Sell |
1,390
-4
| -0.3% | -$1.27K | 0.23% | 80 |
|
|
2022
Q2 | $452K | Hold |
1,394
| – | – | 0.22% | 83 |
|
|
2022
Q1 | $399K | Sell |
1,394
-5
| -0.4% | -$1.29K | 0.16% | 92 |
|
|
2021
Q4 | $386K | Hold |
1,399
| – | – | 0.14% | 96 |
|
|
2021
Q3 | $323K | Hold |
1,399
| – | – | 0.14% | 100 |
|
|
2021
Q2 | $378K | Hold |
1,399
| – | – | 0.16% | 96 |
|
|
2021
Q1 | $261K | Sell |
1,399
-2
| -0.1% | -$391 | 0.13% | 109 |
|
|
2020
Q4 | $237K | Hold |
1,401
| – | – | 0.12% | 115 |
|
|
2020
Q3 | $207K | Sell |
1,401
-321
| -19% | -$49.7K | 0.11% | 123 |
|
|
2020
Q2 | $283K | Hold |
1,722
| – | – | 0.18% | 89 |
|
|
2020
Q1 | $266K | Buy |
1,722
+52
| +3% | +$7.14K | 0.18% | 92 |
|
|
2019
Q4 | $219K | Sell |
1,670
-5
| -0.3% | -$580 | 0.14% | 99 |
|
|
2019
Q3 | $187K | Buy |
1,675
+1
| +0.1% | +$111 | 0.13% | 109 |
|
|
2019
Q2 | $185K | Hold |
1,674
| – | – | 0.13% | 111 |
|
|
2019
Q1 | $217K | Buy |
1,674
+33
| +2% | +$4.01K | 0.17% | 94 |
|
|
2018
Q4 | $190K | Hold |
1,641
| – | – | 0.17% | 98 |
|
|
2018
Q3 | $174K | Buy |
1,641
+20
| +1% | +$2K | 0.12% | 109 |
|
|
2018
Q2 | $153K | Hold |
1,621
| – | – | 0.1% | 128 |
|
|
2018
Q1 | $125K | Hold |
1,621
| – | – | 0.09% | 139 |
|
|
2017
Q4 | $137K | Buy |
+1,621
| New | +$138K | 0.11% | 132 |
|
Other funds holding LLY
Front Row Advisors's LLY Position: Q2 2026 in Review
Front Row Advisors held its Eli Lilly (LLY) position steady in Q2 2026 at 287 shares worth $349K. The position accounts for 0.1% of the portfolio, ranked #89.
Front Row Advisors first reported a position in LLY in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.18M in Q1 2024. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Front Row Advisors held 287 shares of Eli Lilly worth $349K as of Q2 2026.
- Front Row Advisors left its Eli Lilly share count unchanged in Q2 2026.
- Eli Lilly made up 0.1% of Front Row Advisors's portfolio in Q2 2026, its #89 holding.
- Front Row Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 35 quarters since.
- Front Row Advisors's Eli Lilly position peaked at $1.18M in Q1 2024.
- 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.